Update on Diabetic Kidney Disease

In this presentation, Dr. Sankar Dass Navaneethan, Associate Professor of Medicine in the Section of Nephrology at Baylor College of Medicine, discusses the growing burden of diabetic kidney disease (DKD), the effects on intensive glucose control on DKD, and the various management strategies for DKD. He explains the role of novel oral hypoglycemic agents, specifically SGLT2 inhibitors and GLP-1 receptor agonists,in slowing the development of microalbuminuria and proteinuria in diabetic patients. 

Dr. Navaneethan also describes the management of obesity in patients with DKD and highlights the need for a multidisciplinary team to manage DKD and its related comorbidities.

Disclosures

The following individual(s) has/have reported financial or other relationship(s) with commercial entities whose products/services may relate to the educational content of this activity:

Presenter

  1. Sankar Dass Navaneethan, M.D., M.S., M.P.H.

    Sankar Dass Navaneethan, M.D., M.S., M.P.H.

    Associate Professor
    Baylor College of Medicine

    Disclosure:

    Nothing to disclose.